[1] Yamamoto T, Takagawa S, Katayama I, et al. Anti sclerotic effect of TGF-β antibody in a mouse model of bleomycin induced scleroderma. Clin Immunol, 1999, 92: 6-13. [2] Santos RM, Norton P, Degli Esposti S, et al. TGF-β isoforms in alcoholic liver disease. J Gastroenterol, 1998, 33: 383-389. [3] Shimizu M, Saitoh Y, Itoh H, et al. Immunohistochemical staining of ha ras oncogene product in normal, benign, and malignant human pancreatic tissues. Human Pathol, 1990, 21: 607-613. [4] Higley H, Persichitte S, Chu S,et al.Immunocytochemical localization and serologic detection of transforming growth factor β 1. Association with type Ⅰ procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud' s phenomenon. Arthritis Rheum, 1994, 37: 278-288. [5] Gruschwitz M, Muller PU, Sepp N, et al. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol, 1990, 94: 197-203. [6] Kulozik M, Hogg A, Lankat-Buttgereit B, et al. Co localization of transforming growth factor beta 2 with alpha 1(Ⅰ) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest, 1990, 86: 917-922. [7] Kawakami T, Ihn H, Xu W, et al. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phentotype. J Invest Dermatol, 1998, 110: 47-51. [8] 洪微,廖万清,孔宪涛,等. 成纤维细胞与纤连蛋白粘附及其诱导的酪氨酸磷酸化蛋白在硬皮病原胶原基因表达中的作用. 中华皮肤科杂志,1999, 32: 243-244. |